CTLA-4 – Immunotherapy: Attacking melanoma with checkpoint inhibitors.

Hodi and his colleagues have worked to better understand which patients with melanoma are likely to be helped by Ipilimumab, and to extend the drug’s benefits to a larger percentage of patients.

Pictured above:  Stephen F. Hodi, MD, Director, Melanoma Center; Director, Center for Immuno-Oncology